Clinical Trial

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

Study acronym: SOCCER-P
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-01-19; most recent amendment 2025-03-03.
Status change: Not Yet Recruiting → Recruiting 2024-03-09
Trial Details
NCT Number NCT05704621
Lead Sponsor Korea University Guro Hospital
Collaborators: Boryung Pharmaceutical Co., Ltd, Chong Kun Dang Pharmaceutical Corp., Yonsei University, KGOG: Korean Gynaelogical Onology Group, Korea, Japanese Gynecologic Oncology Group, Asia-Pacific Gynecologic Oncology Trials Group
Conditions Ovarian Cancer, Drug Related Neoplasm/Cancer
Enrollment 124 participants
Start Date 2023-12-01
Primary Completion 2026-12-28 (estimated)
Study Completion 2028-12-28 (estimated)
Updated on ClinicalTrials.gov 2025-03-06